Published in Genet Med on February 01, 2008
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet (2012) 2.07
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther (2014) 1.93
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
Personalised medicine: not just in our genes. BMJ (2012) 1.51
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med (2016) 1.16
Clinically available pharmacogenomics tests. Clin Pharmacol Ther (2009) 1.13
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn (2010) 1.06
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev (2008) 0.94
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Balancing personalized medicine and personalized care. Acad Med (2013) 0.88
Pharmacogenetics education in British medical schools. Genomic Med (2009) 0.88
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genet Med (2014) 0.84
Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment). PLoS Curr (2010) 0.84
Next generation DNA sequencing and the future of genomic medicine. Genes (Basel) (2010) 0.84
A mutation-centric approach to identifying pharmacogenomic relations in text. J Biomed Inform (2012) 0.83
Personalized medicine: a patient-centered paradigm. J Transl Med (2011) 0.83
Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr Opin Cardiol (2009) 0.83
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Pharmacogenetics of anxiolytic drugs. J Neural Transm (Vienna) (2009) 0.83
Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen. Drug Metab Dispos (2013) 0.82
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Warfarin genotyping using three different platforms. Am J Transl Res (2010) 0.80
Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmgenomics Pers Med (2016) 0.80
Progress toward personalized medicine for glaucoma. Expert Rev Ophthalmol (2009) 0.80
Personalized vascular medicine: individualizing drug therapy. Vasc Med (2011) 0.79
Assessing the Genetics Content in the Next Generation Science Standards. PLoS One (2015) 0.78
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78
Expanded genetic screening panel for the Ashkenazi Jewish population. Genet Med (2015) 0.77
Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Syst Rev (2016) 0.77
Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging (2013) 0.77
Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol (2011) 0.77
Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci (2014) 0.77
Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? EPMA J (2012) 0.76
Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol (2012) 0.76
Prescribing warfarin appropriately to meet patient safety goals. Am Health Drug Benefits (2008) 0.75
Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays. Clin Chim Acta (2010) 0.75
Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine? AMIA Annu Symp Proc (2009) 0.75
Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy. Int J Hematol Oncol Stem Cell Res (2015) 0.75
Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study. J Law Med Ethics (2016) 0.75
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. Eur J Clin Pharmacol (2017) 0.75
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet (2010) 13.70
ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med (2008) 9.13
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
ACMG clinical laboratory standards for next-generation sequencing. Genet Med (2013) 5.30
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
ClinGen--the Clinical Genome Resource. N Engl J Med (2015) 4.45
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem (2004) 3.99
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med (2011) 3.21
Pompe disease diagnosis and management guideline. Genet Med (2006) 3.03
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst (2012) 2.52
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol (2009) 2.45
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med (2009) 2.39
Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci (2005) 2.39
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A (2003) 2.29
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Glycogen storage disease type III diagnosis and management guidelines. Genet Med (2010) 2.13
The GeneInsight Suite: a platform to support laboratory and provider use of DNA-based genetic testing. Hum Mutat (2011) 2.08
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Standards and guidelines for CFTR mutation testing. Genet Med (2002) 1.94
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest (2009) 1.82
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Intramedullary tibial nailing in distal third tibial fractures: distal locking screws and fracture non-union. Int Orthop (2007) 1.71
Etiology of sudden death in the community: results of anatomical, metabolic, and genetic evaluation. Am Heart J (2010) 1.70
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology (2009) 1.61
Crossing the omic chasm: a time for omic ancillary systems. JAMA (2013) 1.59
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol (2008) 1.57
Direct molecular haplotyping of the IVS-8 poly(TG) and polyT repeat tracts in the cystic fibrosis gene by melting curve analysis of hybridization probes. Clin Chem (2005) 1.56
Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genet Med (2013) 1.55
Clinician perspectives about molecular genetic testing for heritable conditions and development of a clinician-friendly laboratory report. J Mol Diagn (2009) 1.54
Electronic medical records and personalized medicine. Hum Genet (2011) 1.52
Evidence-based decision support for neurological diagnosis reduces errors and unnecessary workup. J Child Neurol (2013) 1.50
Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet (2009) 1.47
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model. Am J Clin Pathol (2005) 1.44
Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med (2012) 1.44
Type II phosphoinositide 5-phosphatases have unique sensitivities towards fatty acid composition and head group phosphorylation. FEBS Lett (2004) 1.42
Leveraging the electronic health record to implement genomic medicine. Genet Med (2012) 1.42
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Likelihood ratios to assess genetic evidence for clinical significance of uncertain variants: hereditary hemorrhagic telangiectasia as a model. Exp Mol Pathol (2008) 1.40
Ordering molecular genetic tests and reporting results: practices in laboratory and clinical settings. J Mol Diagn (2008) 1.40
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39
Medical foods: inborn errors of metabolism and the reimbursement dilemma. Genet Med (2010) 1.38
Distinguishing different DNA heterozygotes by high-resolution melting. Clin Chem (2005) 1.38
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med (2011) 1.34
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn (2010) 1.34
Opportunities for genomic clinical decision support interventions. Genet Med (2013) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist (2006) 1.30
Relationship between the National ED Overcrowding Scale and the number of patients who leave without being seen in an academic ED. Am J Emerg Med (2005) 1.28
Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. Eur J Epidemiol (2009) 1.25
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum (2004) 1.25
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting. J Mol Diagn (2007) 1.23
Developing a sustainable process to provide quality control materials for genetic testing. Genet Med (2005) 1.23
Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology (2004) 1.22
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat (2008) 1.21
Competencies for the physician medical geneticist in the 21st century. Genet Med (2011) 1.21
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy (2010) 1.21
Discovering rare variants by use of melting temperature shifts seen in melting curve analysis. Clin Chem (2005) 1.21
Multilevel research and the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr (2012) 1.21
Diagnostic performance of cyst fluid carcinoembryonic antigen and amylase in histologically confirmed pancreatic cysts. Pancreas (2011) 1.20